Global Microrna Expression Profiling Uncovers Molecular Markers for Classification and Prognosis in Aggressive B-cell Lymphoma.
Javeed Iqbal,Yulei Shen,Xin Huang,Yanyan Liu,Laura Wake,Cuiling Liu,Karen Deffenbacher,Cynthia M. Lachel,Chao Wang,Joseph Rohr,Shuangping Guo,Lynette M. Smith,George Wright,Sharathkumar Bhagavathi,Karen Dybkaer,Kai Fu,Timothy C. Greiner,Julie M. Vose,Elaine Jaffe,Lisa Rimsza,Andreas Rosenwald,German Ott,Jan Delabie,Elias Campo,Rita M. Braziel,James R. Cook,Raymond R. Tubbs,James O. Armitage,Dennis D. Weisenburger,Louis M. Staudt,Randy D. Gascoyne,Timothy W. McKeithan,Wing C. Chan
DOI: https://doi.org/10.1182/blood-2014-04-566778
IF: 20.3
2015-01-01
Blood
Abstract:We studied the global microRNA (miRNA) expression in diffuse large B-cell lymphoma (DLBCL; n = 79), Burkitt lymphoma (BL; n = 36), primary mediastinal B-cell lymphoma (PMBL; n = 12), B-cell lines (n = 11), and normal subsets of naive B cells, centroblasts (CBs), and peripheral blood B cells along with their corresponding gene expression profiles (GEPs). The normal B-cell subsets have well-defined miRNA signatures. The CB miRNA signature was significantly associated with germinal center B-cell (GCB)-DLBCL compared with activated B-cell (ABC)-DLBCL (P = .002). We identified a 27-miRNA signature that included v-myc avian myelomatosis viral oncogene homolog(MYC) targets and enabled the differentiation of BL from DLBCL, a distinction comparable with the "gold standard" GEP-defined diagnosis. Distinct miRNA signatures were identified for DLBCL subgroups, including GCB-DLBCL, activated B-cell (ABC)-DLBCL, and PMBL. Interestingly, most of the unclassifiable-DLBCL by GEP showed a strong similarity to the ABC-DLBCL by miRNA expression profiling. Consistent results for BL and DLBCL subgroup classification were observed in formalin-fixed, paraffin-embedded tissue, making such tests practical for clinical use. We also identified predictive miRNA biomarker signatures in DLBCL, including high expression of miR-155, which is significantly associated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treatment failure. This finding was further supported by the observation that high expression of miR-155 sensitizes cells to v-akt murine thymoma viral oncogene homolog-1 inhibitors in vitro, suggesting a novel treatment option for resistant DLBCL.